Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age above or equal to 18 years at the time of signing informed consent.~* Diagnosed with type 2 diabetes mellitus at least 180 days prior to the day of screening.~* HbA1c of 8.0-10.5% (64-91 mmol/mol) (both inclusive).~* BMI equal to or above 25 kg/m\^2~* Stable daily dose(s) for 90 days prior to the day of screening of any of the following treatment regimens:~* No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a \*:~  * Metformin (equal to or above1500 mg or maximum tolerated or effective dose).~ * Sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose).~ * Sodium/glucose cotransporter 2 (SGLT2) inhibitors (maximum tolerated dose).~* Dipeptidyl peptidase-4 (DPP-4) inhibitors (maximally indicated dose as per local label).~* Subjects, on treatment with stable dose of DPP-4 inhibitors at inclusion, must be willing to discontinue DPP-4 inhibitor treatment at randomisation (with no wash-out).~Exclusion Criteria:~* Treatment with any medication indicated for the treatment of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed.~* Renal impairment measured as estimated glomerular filtration rate (eGFR) value of below 30 mL/min/1.73 m\^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO 2012) classification.~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral semaglutide 50 mg (Type: EXPERIMENTAL): Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68).
- Oral semaglutide 25 mg (Type: EXPERIMENTAL): Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12) and 25 mg (week 13-68).
- Oral semaglutide 14 mg (Type: ACTIVE_COMPARATOR): Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8) and 14 mg (week 9-68).

Based on this trial design, predict the completion outcome and termination type (if applicable).